POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (5.10.2021, 11:04am CEST, WHO):   U.S. 34,155    India 366,161    Brazil 63,430    France 20,745    Turkey 18,052    Russia 8,419    The United Kingdom 2,047    Italy 10,174    Germany 12,656    Argentina 18,024    Columbia 16,910    Poland 3,856    Iran 14,141    Mexico 2,743    Ukraine 5,372    Peru 5,591    Indonesia 3,922    South Africa 2,191    The Netherlands 7,521    Canada 6,802    Chile 6,198    Iraq 4,167    Philippines 7,156    Romania 1,305    Pakistan 3,786    Hungary 1,145    Bangladesh 1,386    Serbia 1,056    Japan 7,017    Austria 1,251    United Arab Emirates 1,572    Malaysia 3,733    Ecuador 1,375    Nepal 8,777    Belarus 1,369    Greece 2,461    Georgia 1,089    Tunisia 1,301    Bolivia 1,394    Paraguay 2,073    Egypt 1,138    Guatemala 1,393    Uruguay 2,654    Venezuela 1,368    Oman 2,006    Bahrain 1,451    Sri Lanka 2,672    Cuba 1,069    Thailand 1,630    Maldives 1,091    China 13    Singapore 28    New Zealand 2    Australia 17    South Korea 463   

Cuba's medicine will be tested in U.S., Mexico and Brazil

Christian Fernsby |
The monoclonal antibody Itolizumab received authorization to start a phase III clinical trial in coronavirus patients in the U.S., Mexico and Brazil, reported Cuba's Center for Molecular Immunology (CIM).

Article continues below




Developed by that institution in collaboration with the India's BIOCON company, this trial will consolidate the scientific pieces of evidence that supports the effective inclusion of the drug in the Cuba's protocol for the coronavirus treatment, warns the CIM on Twitter.

Winner of one of the National Awards of the Cuban Academy of Sciences in 2014, in the Biomedical Sciences category, the product has an anti inflammatory and immuno regulatory effect.

Recently, Cuban researchers also shared on social networks an article published in the Gerontology Journal about the country's experience of Itolizumab's use in elderly coronavirus patients.

According to the text, the study combined the timely use of this monoclonal antibody with other antiviral and anticoagulant therapies to reduce the worsening of coronavirus and mortality.

Experts assured that this innovative product of Cuban biotechnology allowed reducing the number of critical patients.


What to read next

Cuba presents second vaccine candidate against coronavirus for evaluation
More children with ADHD could benefit from behavior therapy
Miami-Dade mosquitoes test positive for Zika